As recent studies in HER2low (HER2 score 1+ or 2+) breast cancer suggest, combined detection of ERBB2 by FISH and NGS can be used for subtyping tumors with ERBB2 alterations or amplifications [30,31]. This evidence concerns the gene ERBB2 and breast carcinoma.